Dr. Brian T. Hess, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 274
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Missouri, Columbia School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
SC license 39373 -
Hematology & Oncology Physician
MO license 2013015488 · SC license 39373 -
Internal Medicine Physician
IL license 125-058489
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Musc Medical Center Charleston, SC
- Musc Health Columbia Medical Center Downtown Columbia, SC
- Musc Health Florence Medical Center Florence, SC
Medical groups
- University Medical Associates of the Medical University of South Carol (1,668 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 274
- Services billed
- 545
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 241 | 153 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 118 | 39 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 102 | 39 |
| New patient office or other outpatient visit, 60-74 minutes | 64 | 64 |
| Established patient office or other outpatient visit, 20-29 minutes | 48 | 45 |
| Established patient office or other outpatient visit, 40-54 minutes | 25 | 22 |
| Hospital discharge day management, more than 30 minutes | 17 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Charleston, SC | 78 |
| Brukinsa (zanubrutinib) | 67 |
| Allopurinol Other prescribers in Charleston, SC | 28 |
| Prednisone Other prescribers in Charleston, SC | 21 |
| Ondansetron Hcl Other prescribers in Charleston, SC | 16 |
| Calquence (acalabrutinib maleate) | 15 |
| Udenyca (pegfilgrastim-cbqv) | 14 |
| Revlimid (lenalidomide) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $4,167 in total to this clinician.
| Gilead Sciences, Inc. | $2,060 |
|---|---|
| Incyte Corporation | $2,055 |
| Genentech, Inc. | $52.12 |
| Consulting Fee | $4,115 |
|---|---|
| Food and Beverage | $52.12 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Dec 3, 2025 | Consulting FeeCompany’s description;4274075;GTF;10584857 | $2,060 |
| Incyte Corporation Jun 12, 2025 | Consulting Fee | $2,055 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $132,079 in research payments for these studies, mostly to the institutions running them.
- Trial of consolidation therapy following CD19 CAR T cell treatment for Relapsed Refractory DLBCL or
Genentech, Inc. - A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.
Genmab U.S., Inc. - Multiple part clinical trial of brentuximab vedotin in classical hodgkin lymphoma subjects
Pfizer Inc. - A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Acerta Pharma LLC - M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated …
AbbVie Inc. - A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
AstraZeneca Pharmaceuticals LP - Polarix
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.